ALS drug trial halted: no clear benefit seen

NCT ID NCT06441682

First seen Nov 20, 2025 · Last updated May 16, 2026 · Updated 20 times

Summary

This study tested an experimental drug called ARGX-119 in 60 adults with ALS to see if it was safe and could slow the disease. The trial was stopped early because early results showed the drug was unlikely to help patients meaningfully. No safety concerns caused the early stop, and researchers are still following up with participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Aarhus Universitets Hospital

    Aarhus, 8200, Denmark

  • Akademiskt specialistcentrum Karolinska Institutet

    Stockholm, 113 61, Sweden

  • Bispebjerg University Hospital

    Copenhagen, 2400, Denmark

  • CHU Bretonneau

    Tours, 37000, France

  • Hôpital La Pitié Salpêtrière

    Paris, 75013, France

  • Kaye Edmonton Clinic

    Edmonton, 11400, Canada

  • Montreal Neurological Institute and Hospital

    Montreal, H3A 2B4, Canada

  • UMC Utrecht

    Utrecht, 3584 CX, Netherlands

  • UZ Leuven

    Leuven, 3000, Belgium

Conditions

Explore the condition pages connected to this study.